Thailand to Consider Special Law Restricting E-Cigarette Use: Reports

Aug.06.2024
Thailand to Consider Special Law Restricting E-Cigarette Use: Reports
Thai Public Health Deputy Minister pushes for new law to restrict e-cigarette use and sales in response to ineffective regulations.

According to a report in the Bangkok Post, the Deputy Minister of Public Health in Thailand recently called for the creation of specific laws to restrict the use and sale of e-cigarettes, noting that current regulations are ineffective.


In a discussion at the National Health Committee office in Thailand, Deputy Minister of Public Health Thanakrit Jitareerat emphasized that there are currently no specific laws regarding e-cigarettes. Despite the establishment of a dedicated team within the Public Health Ministry to study this issue, he pointed out that each agency independently enforces measures based on different laws.


He said:


The measures we have implemented so far have been ineffective, therefore it is necessary to draft specific laws addressing this issue as soon as possible, considering e-cigarettes as a serious threat to society.


He also criticized government officials who continue to use e-cigarettes despite the ban, believing that this is hindering progress in the fight against vaping.


The Chairman of the National Health Commission Office, Banjerd Singkaneti, stated that the Prime Minister should prioritize refining existing laws to provide clearer guidance for authorities.


In the long term, the law should clearly prohibit the possession of e-cigarettes to prevent law enforcement from having any excuses not to enforce legal responsibilities.


Benjie said. He also suggested that if e-cigarette sales are found in a certain area, the relevant government officials should be held accountable.


According to a report from the Office of the Consumer Protection Commission in Thailand, the number of seized e-cigarettes has significantly increased from 27,000 in 2020 to 100,000 in 2023.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
The U.S. Food and Drug Administration (FDA) announced on May 5, 2026 that it authorized the marketing of four Glas electronic nicotine delivery system (ENDS) products through the premarket tobacco product application (PMTA) pathway. The authorized products are Classic Menthol, Fresh Menthol, Gold and Sapphire pods, each containing 50mg/ml, or 5%, tobacco-derived nicotine.
May.06 by 2FIRSTS.ai
European Commission Publishes Tobacco Control Framework Evaluation, Says Smoking and Tobacco-Related Deaths Have Declined
European Commission Publishes Tobacco Control Framework Evaluation, Says Smoking and Tobacco-Related Deaths Have Declined
The European Commission has published its evaluation of the EU tobacco control framework, assessing the effectiveness, efficiency and relevance of the Tobacco Products Directive and Tobacco Advertising Directive in protecting public health and ensuring the smooth functioning of the internal market.
Apr.03 by 2FIRSTS.ai
BAT Appoints Constantinescu as CFO,He Previously Spent 16 Years at the Company
BAT Appoints Constantinescu as CFO,He Previously Spent 16 Years at the Company
BAT has appointed Dragos Constantinescu as chief financial officer. Constantinescu, currently head of Asahi Europe & International, will join the company on September 1 and replace Javed Iqbal, who has served as interim finance chief since August last year
Apr.09 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business
Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business
Jinjia Shares’ 2025 annual report summary and first-quarter 2026 report show that the company recorded 2025 revenue of RMB 2.988 billion, up 4.57% year on year, while net profit attributable to shareholders turned to a loss of RMB 346 million. In the first quarter of 2026, revenue rose 58.13% year on year to RMB 1.005 billion, but attributable net profit fell 45.16% to RMB 36.5349 million. The company said both revenue and cost growth were related to the expansion of its new tobacco business.
Apr.28 by 2FIRSTS.ai
Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Researchers at the Chinese Academy of Sciences reconstructed nicotine biosynthesis in non-tobacco plants and yeast systems, highlighting how advances in synthetic biology could gradually reshape future nicotine production technologies and challenge regulatory frameworks built around tobacco-derived definitions.
Special Report
May.07